Nantahala Capital Management, LLC Chemo Centryx, Inc. Transaction History

Nantahala Capital Management, LLC

$1.68 Billion
Q3 2024

Shares

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2020 Nov 16, 2020	SELL	$46.35 - $61.69 $225,214 - $299,751	-4,859 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$38.58 - $65.07 $187,460 - $316,175	4,859 New	4,859 $280,000
Q1 2019 May 15, 2019	SELL	$10.01 - $13.89 $6.24 Million - $8.66 Million	-623,338 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$9.15 - $12.26 $183,000 - $245,200	-20,000 Reduced 3.11%	623,338 $6.8 Million
Q3 2018 Nov 14, 2018	BUY	$10.49 - $13.72 $295,450 - $386,423	28,165 Added 4.58%	643,338 $8.13 Million
Q2 2018 Aug 14, 2018	BUY	$10.62 - $13.98 $155,954 - $205,296	14,685 Added 2.45%	615,173 $8.1 Million
Q1 2018 May 15, 2018	SELL	$5.9 - $14.99 $2.03 Million - $5.17 Million	-344,586 Reduced 36.46%	600,488 $8.17 Million
Q4 2017 Feb 14, 2018	BUY	$5.53 - $8.42 $1.48 Million - $2.25 Million	267,295 Added 39.44%	945,074 $5.62 Million
Q3 2017 Nov 14, 2017	BUY	$6.5 - $10.69 $4.41 Million - $7.25 Million	677,779	677,779 $5.03 Million

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nantahala Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nantahala Capital Management, LLC with notifications on news.